ADVANCES IN ADJUVANT THERAPY FOR RESECTED NON SMALL CELL LUNG CANCER

Abstract

Non Small Cell Lung Cancer (NSCLC) is the second most common cancer in both sex but it is still the leading cause of cancer death. Most of NSCLN appear in the late stage so the prognosis is very poor. Although, the patient in early stage NSCLC who underwent standard lobectomy but the recurrent rate is still so high. Adjuvant therapy after standard surgical therapy gives the patient better overall survival (OS) and disease Free Survival (DFS). Recent advances in diagnosis and treatment for NSCLC show the benefit of adjuvant therapy with TKI or Immunotherapy for selected NSCLC patients.